Introduction
============

In living organisms, communication between individual cells and between cells and the environment plays essential roles in various cellular processes including growth, differentiation, migration, and apoptosis.[@b1-itt-4-035] These cellular processes are mediated in large part by signaling pathways triggered by interactions between receptor tyrosine kinases (RTKs) and their ligands.[@b1-itt-4-035] Upon ligand binding, RTKs on the cell surface activate downstream signaling cascades and regulate target gene expression in a paracrine or autocrine manner.[@b1-itt-4-035] These signaling pathways mediated by RTKs and their ligands are critical for both regulation of diverse cellular processes and development and progression of cancers.[@b2-itt-4-035]--[@b4-itt-4-035] RTK-mediated signaling pathways are tightly regulated according to the physiological status of normal cells. In contrast, RTK signaling pathways are dysregulated or hyperactivated in a wide range of cancers via gain-of-function mutations, gene rearrangements, gene amplifications, and overexpression or abnormal stimulation of receptors/ligands.[@b1-itt-4-035]--[@b4-itt-4-035] Furthermore, it has been suggested that loss-of-function by deletion or mutation of RTKs, including fibroblast growth factor receptor 1, EphA, and c-Met, is associated with several diseases, including cancers.[@b5-itt-4-035]--[@b7-itt-4-035] Thus, RTK-mediated signaling pathways have become promising therapeutic targets for treating cancer.[@b2-itt-4-035]--[@b4-itt-4-035]

Individual RTK-mediated signaling cascades can be targeted at several levels to develop anti-cancer therapeutic agents that inhibit the signaling pathways via disruption of interactions between RTKs and their ligands, dimerization and phosphorylation of RTKs, and activation of downstream elements.[@b2-itt-4-035],[@b4-itt-4-035] For monoclonal antibody-based therapeutics, RTK-mediated signaling pathways are mainly inhibited by disrupting interactions between RTKs and their ligands.[@b4-itt-4-035] Compared with small-molecule compounds that inhibit the kinase activity and autophosphorylation of a broad spectrum of RTKs, antibody inhibitors have greater target specificity for particular RTKs and/or ligands. Several antibody-based therapeutic agents that inhibit RTK-mediated signaling pathways have already been approved for the treatment of human cancers.[@b4-itt-4-035] Trastuzumab (Herceptin™, Genentech/Roche, South San Francisco, CA, USA; approved by the US Food and Drug Administration \[FDA\] in 1998) binds to human epidermal growth factor receptor 2 (HER2)/neu receptor and is used to treat breast cancer.[@b8-itt-4-035] Bevacizumab (Avastin™, Genentech/Roche; approved by the FDA in 2004) binds to vascular endothelial growth factor (VEGF) and is used to treat colorectal cancer, metastatic renal cell carcinoma, recurrent glioblastoma, and non-small cell lung cancer (NSCLC).[@b9-itt-4-035]--[@b12-itt-4-035] Both cetuximab (Erbitux™; developed by Bristol-Myers Squibb, New York, NY, USA/Eli Lilly, Indianapolis, IN, USA and Merck KGaA, Darmstadt, Germany and approved in 2004) and panitumumab (Vectibix™, developed by Amgen (Thousand Oaks, CA, USA) and approved in 2006) bind to epidermal growth factor receptor (EGFR) and are used to treat colorectal and head/neck cancers.[@b13-itt-4-035],[@b14-itt-4-035] Ramucirumab (Cyramza™, developed by Eli Lilly and approved in 2014) binds to VEGF receptor 2 and is used to treat gastric cancer.[@b15-itt-4-035] Although these FDA-approved therapeutic antibodies have contributed to improving clinical outcomes, there are still unmet needs for difficult-to-treat cancers. Identification of additional RTK/ligand targets may enable more effective treatment of these cancers.[@b2-itt-4-035]--[@b4-itt-4-035] Currently, a variety of novel antibody-based inhibitors targeting RTKs such as c-Met, fibroblast growth factor receptor, HER1, HER3, insulin-like growth factor-1 receptor, platelet-derived growth factor receptor, and RON (recepteur d'origine nantais) are in preclinical and clinical development.[@b4-itt-4-035]

c-Met, the RTK oncogene, was first cloned in 1984.[@b16-itt-4-035] The ligand of c-Met, hepatocyte growth factor (HGF; also known as scatter factor) was identified in 1991 as a potent mitogen/morphogen.[@b17-itt-4-035],[@b18-itt-4-035] The HGF/c-Met signaling pathway has been demonstrated to play important roles in the development and progression of various cancers.[@b19-itt-4-035]--[@b21-itt-4-035] Dysregulation and hyperactivation of HGF or c-Met have been reported in human cancers and linked to poor prognosis.[@b22-itt-4-035],[@b23-itt-4-035] It has been suggested that the HGF/c-Met signaling pathway may be a promising target for drugs designed to overcome development of resistance to inhibition of other ligand/RTK signaling pathways.[@b19-itt-4-035]--[@b21-itt-4-035] A large number of inhibitors of the HGF/c-Met signaling pathway are under development to treat human cancers.[@b19-itt-4-035]--[@b21-itt-4-035] Similar to other inhibitors of RTK-mediated signaling pathways, agents targeting HGF or c-Met are categorized into two groups, ie, small-molecule drugs and biologics such as monoclonal antibodies.[@b19-itt-4-035]--[@b21-itt-4-035] Currently, multiple therapeutic antibodies targeting the HGF/c-Met signaling pathway are in preclinical or clinical development.[@b24-itt-4-035] In this review, we summarize the role of HGF and c-Met in normal tissues and cancers. We then discuss the development of HGF/c-Met signaling pathway inhibitors for cancer treatment, including critical issues in clinical development and future perspectives focusing on monoclonal antibody-based therapeutics.

Physiological role of HGF and c-Met
===================================

The HGF/c-Met signaling pathway influences a variety of cellular functions to control diverse biological processes such as embryonic development, epithelial branching morphogenesis, postnatal organ regeneration, and wound healing ([Figure 1](#f1-itt-4-035){ref-type="fig"}).[@b19-itt-4-035]--[@b21-itt-4-035] HGF is a paracrine signaling molecule produced and secreted from mesenchymal cells to affect neighboring epithelial cells expressing c-Met. Protective roles of HGF have been reported in tissue fibrosis, liver cirrhosis, endothelial injury, and lung fibrosis.[@b25-itt-4-035]--[@b29-itt-4-035]

HGF is produced as an inactive single-chain precursor that is processed to yield an active heterodimer of one alpha and one beta chain linked by a disulfide bond.[@b30-itt-4-035],[@b31-itt-4-035] c-Met is also produced as a single-chain precursor and processed to yield a mature receptor composed of a glycosylated, extracellular alpha subunit disulfide-bonded to a transmembrane beta subunit.[@b32-itt-4-035] The extracellular portion of c-Met is composed of a Sema domain (homologous to semaphorins), a cysteine-rich, Met-related-sequence domain, and four immunoglobulin (Ig)-like modules (IgG domains) responsible for binding HGF.[@b32-itt-4-035] The intracellular portion of c-Met is composed of a juxtamembrane domain, a tyrosine kinase domain, and a C-terminal regulatory tail responsible for signal transduction.[@b33-itt-4-035] Tyrosine residues Tyr 1234 and Tyr 1235 in the tyrosine kinase domain regulate the kinase activity of c-Met, and tyrosine residues Tyr 1349 and Tyr 1356 in the C-terminal regulatory tail (the multisubstrate docking site) are important for recruitment of downstream adapters, including growth factor receptor-bound protein 2 (GRB2) protein and GRB2-associated binding protein 1 (GAB1) ([Figure 1](#f1-itt-4-035){ref-type="fig"}).[@b34-itt-4-035],[@b35-itt-4-035] HGF/c-Met signaling through these downstream effectors stimulates diverse cellular processes such as cell proliferation, differentiation, migration, invasion, and survival ([Figure 1](#f1-itt-4-035){ref-type="fig"}).[@b19-itt-4-035]--[@b21-itt-4-035]

Mice lacking either HGF or c-Met exhibit embryonic lethality due to incomplete liver development.[@b36-itt-4-035],[@b37-itt-4-035] In addition, loss of HGF signaling in mice decreases proliferation of gastric mucosal cells and delays recovery from mucosal injury.[@b38-itt-4-035] Depletion of c-Met in cancer cells results in the inhibition of cell proliferation, invasion, and survival, suggesting an essential role of c-Met in the development, progression, and invasion of cancers.[@b39-itt-4-035]--[@b42-itt-4-035]

Role of HGF and c-Met in cancer
===============================

In addition to the developmental roles described above, the HGF/c-Met signaling pathway is highly activated in human cancers via overexpression, amplification, or mutation, and promotes development, progression, invasive growth, and metastasis of cancers.[@b43-itt-4-035] Abnormal expression of HGF and c-Met has been reported in various solid tumors, including breast, colon, lung, ovary, kidney, and liver cancers ([Table 1](#t1-itt-4-035){ref-type="table"}).[@b44-itt-4-035],[@b45-itt-4-035] HGF secretion from tumor stromal cells has been correlated with overexpression of c-MET. Overexpression of HGF/c-Met has been reported in breast, colon, lung, ovarian, and renal cancer.[@b44-itt-4-035],[@b45-itt-4-035] HGF/c-Met over-expression has also been correlated with metastasis and poor survival in hepatocellular carcinoma, renal cell carcinoma, and breast cancer.[@b46-itt-4-035]--[@b50-itt-4-035]

Both germline and somatic mutations in c-Met have been reported in various cancers. These mutations increase tumorigenic potential via constitutive activation of the c-Met receptor.[@b51-itt-4-035] The mutations are found in the tyrosine kinase domain, juxtamembrane domain, and extracellular domain of c-Met. The activating mutations in the tyrosine kinase domain of c-Met induce different downstream cascades and biological processes. D1228H/N and M1250T mutations increase c-Met phosphorylation and Ras activation, while L1195V and Y1230C mutations activate phosphatidylinositol-4, 5-bisphosphate 3-kinase to promote invasive and anchorage-independent growth.[@b52-itt-4-035]

Amplification of c-Met receptor and overexpression of HGF are associated with resistance to inhibitors targeting other RTKs. Amplification of c-Met activates ERBB3 (HER3)-dependent phosphatidylinositol-4,5-bisphosphate 3-kinase signaling, leading to resistance to gefitinib (a small-molecule inhibitor of EGFR) in lung cancer.[@b53-itt-4-035] In addition, HGF is involved in decreased susceptibility to irreversible EGFR tyrosine kinase inhibition in lung cancer with the EGFR T790M mutation.[@b54-itt-4-035] Similarly, amplification of c-Met is involved in resistance to the anti-EGFR monoclonal antibodies, cetuximab and panitumumab, in metastatic colorectal cancer.[@b55-itt-4-035] Recent studies have demonstrated that the copy number of *HGF* and *MET* genes correlates with sensitivity to treatment with trastuzumab in HER2-positive metastatic breast cancer. An increased copy number for the *MET* gene has been linked to a higher failure rate of trastuzumab treatment and to a shorter time to progression, which means the length of time from the date of diagnosis or the start of treatment for a breast cancer patient until the breast cancer starts to get worse or spreads to other parts of the body. Increased copy number for the *HGF* gene is also linked to a higher failure rate of trastuzumab treatment.[@b56-itt-4-035] These studies on mutation and amplification of *HGF* and *MET* genes provide important information for the development of therapeutic agents targeting the HGF/c-Met signaling pathway.[@b57-itt-4-035],[@b58-itt-4-035] These results indicate that the c-Met receptor, together with other RTK signaling pathways such as ERBB3 (HER3), EGFR, and ERBB2 (HER2), has a synergic role in tumor progression in certain types of cancers. Therefore, combination therapy targeting both c-Met and other RTKs may be more effective for cancer treatment compared with monotherapy.

Antibody-based therapeutics targeting HGF and c-Met
===================================================

Inhibitors of the HGF/c-Met signaling pathway are divided into two groups: while small-molecule compounds block the signaling pathway by inhibiting tyrosine kinase activity and autophosphorylation of c-Met, biologics including truncated HGF, N-terminal Sema domain of HGF, soluble extracellular domain of c-Met (decoy Met), and antibodies against HGF and c-Met suppress the signaling pathway by inhibiting interactions between HGF and c-Met. Compared with small-molecule compounds that often target multiple RTKs, biologics more specifically inhibit the HGF/c-Met signaling pathway. Multiple therapeutic antibodies targeting the HGF/c-Met signaling pathway are currently in preclinical and clinical development ([Table 2](#t2-itt-4-035){ref-type="table"}).

Anti-HGF monoclonal antibodies
------------------------------

Rilotumumab (AMG102, Amgen) is a human monoclonal antibody against HGF that blocks interactions between HGF and its receptor c-Met, thereby inhibiting cellular processes driven by the HGF/c-Met signaling pathway.[@b59-itt-4-035] In a Phase II clinical trial in gastric and esophagogastric junction cancers, rilotumumab in combination with epirubicin, cisplatin, and capecitabine (ECX) has been shown to improve both progression-free survival and overall survival in patients with tumors expressing high levels of c-Met.[@b60-itt-4-035],[@b61-itt-4-035] In this study, patients were given placebo or rilotumumab at 15 mg/kg or 7.5 mg/kg on day 1 in addition to ECX (50 mg/m^2^ epirubicin and 60 mg/m^2^ cisplatin on day 1, and 625 mg/m^2^ capecitabine twice a day on days 1--21) every 3 weeks. Median progression-free survival was 5.1 months for patients treated with rilotumumab 15 mg/kg and 6.8 months for patients treated with rilotumumab 7.5 mg/kg, compared with 4.2 months for the placebo group. Objective response rates reported for patients treated with rilotumumab 15 mg/kg, rilotumumab 7.5 mg/kg and placebo were 31%, 48%, and 21%, respectively. Median overall survival times for patients treated with rilotumumab 15 mg/kg, rilotumumab 7.5 mg/kg, and placebo were 9.7, 11.1, and 8.9 months, respectively. Adverse events, including hematologic adverse events, peripheral edema, and venous thromboembolism, were reported for both the placebo and rilotumumab groups, but were more common in the rilotumumab group. Based on the safety profile and results indicating better efficacy of rilotumumab in combination with ECX, a Phase III study is ongoing in c-Met-positive gastric and gastroesophageal junction cancers (RILOMET-1).[@b61-itt-4-035] The efficacy of rilotumumab has also been demonstrated in metastatic colorectal cancer with wild-type KRAS. In a Phase II clinical trial of rilotumumab in combination with panitumumab (a fully human anti-EGFR monoclonal antibody), the median progression-free survival was 5.2 months for the combination treatment and 3.7 months for treatment with panitumumab alone.[@b62-itt-4-035]

Ficlatuzumab (AV-299; SCH 900105, AVEO Pharmaceuticals, Cambridge, MA, USA) is a humanized monoclonal antibody against HGF that inhibits the HGF-induced c-Met signaling pathway by neutralizing HGF/c-Met binding.[@b63-itt-4-035] Preclinical studies carried out in the H596 NSCLC xenograft model have demonstrated increased anti-cancer activity of ficlatuzumab in combination with an EGFR inhibitor (erlotinib or cetuximab) compared with single agents.[@b64-itt-4-035] In a Phase I study of advanced solid tumors including sarcoma, ovarian cancer, mesothelioma, and glioblastoma multiforme, ficlatuzumab was intravenously administered at 2, 5, 10, or 20 mg/kg once every 2 weeks. At the recommended Phase II dose, ficlatuzumab was administered in combination with erlotinib (150 mg/day). Adverse events including fatigue, peripheral edema, headache, hematologic problems, and pruritus have been reported in the monotherapy group, and common adverse events of rash and diarrhea have been reported in the combination therapy group. From the Phase I study, it has been demonstrated that the selected dose of ficlatuzumab is safe and well tolerated when used in combination with erlotinib at the standard dose.[@b65-itt-4-035],[@b66-itt-4-035] This was followed by a randomized Phase II study with gefitinib alone or in combination with ficlatuzumab to treat NSCLC patients.[@b67-itt-4-035]

TAK-701 (Galaxy Biotech) is a humanized monoclonal antibody that binds to HGF with high affinity.[@b68-itt-4-035] Combination treatment with TAK-701 and gefitinib (a small-molecule inhibitor of EGFR) inhibits the phosphorylation of both c-Met and EGFR and downstream signaling cascades in HCC827-HGF tumor cells (engineered human NSCLC cells that contain an activating EGFR mutation and stably express HGF).[@b68-itt-4-035] Combination treatment with TAK-701 and gefitinib also markedly inhibits tumor growth in HCC827-HGF xenograft models.[@b68-itt-4-035] These results suggest that combination treatment with TAK-701 and gefitinib may provide a means of overcoming resistance to EGFR-tyrosine kinase inhibitor therapy in HGF-induced NSCLC. Phase I studies are ongoing for TAK-701 as a single-agent treatment for advanced solid tumors.

Anti-c-Met monoclonal antibodies
--------------------------------

Onartuzumab (MetMAb, Genentech) is a humanized, monovalent monoclonal antibody against c-Met. Onartuzumab was developed with the knob-into-hole technology, which allows one-to-one interaction between the antibody and the receptor.[@b69-itt-4-035] Onartuzumab potently inhibits binding of HGF, phosphorylation of c-Met, and downstream signaling in the HGF/c-Met pathway with antibody-like pharmacokinetics. Strong anticancer activity has been reported for onartuzumab in preclinical xenograft studies.[@b69-itt-4-035] Activated HGF/c-Met signaling has been associated with a poor prognosis and with resistance to EGFR inhibitors in NSCLC. In a Phase II study, prolonged progression-free survival (2.9 months versus 1.5 months) and overall survival (12.6 months versus 3.8 months) have been reported in c-Met-positive patients treated with erlotinib and onartuzumab compared with patients treated with erlotinib alone.[@b70-itt-4-035] However, in a randomized Phase III trial, combination therapy with onartuzumab and erlotinib failed to confirm the efficacy demonstrated in the Phase II study, as no improvement in overall survival (6.8 months versus 9.1 months) or progression-free survival (2.7 months versus 2.6 months) was observed in c-Met-positive patients.[@b71-itt-4-035] Despite the failure of the Phase III trial, Genentech has continued to develop onartuzumab in two additional Phase III trials in different subgroups of NSCLC, ie, c-Met-positive stage IIIB or IV NSCLC with activating EGFR mutation. Subgroup analyses may provide a means of targeting patients more selectively.[@b72-itt-4-035] Another Phase III clinical trial is ongoing in gastric cancer for evaluation of the efficacy and safety of onartuzumab. In this study, onartuzumab is administered in combination with 5-fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6) to treat metastatic HER2-negative and c-Met-positive gastroesophageal cancer.[@b72-itt-4-035]

Emibetuzumab (LY-2875358, Eli Lilly) is a humanized, bivalent anti-c-Met antibody that inhibits both ligand-dependent and ligand-independent activation of c-Met.[@b73-itt-4-035] In the case of HGF-dependent c-Met activation, emibetuzumab inhibits HGF binding to c-Met, c-Met phosphorylation, and tumor growth both in vitro and in vivo, similar to a humanized, one-armed 5D5 anti-c-Met antibody (precursor of onartuzumab). In the case of HGF-independent c-Met activation by *MET* gene amplification in tumors, emibetuzumab promotes internalization and degradation of c-Met. Decreases in phosphorylated and total c-Met after treatment with emibetuzumab induces inhibition of cell proliferation and tumor growth in the gastric cancer cell lines, MKN-45 and SNU-5, and in the NSCLC cell lines, EBC-1 and H1993. However, the one-armed 5D5 antibody has exhibited no anti-tumor activity in the case of HGF-independent c-Met activation.[@b73-itt-4-035] In a Phase I study, treatment with emibetuzumab alone or in combination with erlotinib resulted in a durable partial response in NSCLC and was also shown to be safe and well tolerated. Based on the pharmacokinetic/pharmacodynamic data, the recommended Phase II dose of emibetuzumab for intravenous administration is 750 mg once every 2 weeks as a single agent or in combination with erlotinib.[@b74-itt-4-035]

ARGX-111 (arGEN-X) is a defucosylated antagonistic anti-c-Met antibody with potent anti-cancer activity based on enhanced antibody-dependent cellular cytotoxicity. A Phase Ib study was initiated in January 2014 to evaluate ARGX-111 in advanced cancers with c-Met overexpression.[@b75-itt-4-035] EM1-mAb (Genmab™, Janssen Research and Development, San Diego, CA, USA) is a bispecific anti-EGFR/c-Met antibody that inhibits both EGFR and c-Met signaling pathways. EM1-mAb has exhibited more potent inhibition of downstream signaling cascades compared with the combination of monospecific antibodies.[@b76-itt-4-035]

Critical analysis for potential of antibody-based HGF/c-Met inhibitors in human cancer
======================================================================================

Several antibody-based inhibitors of the HGF/c-Met signaling pathway are under active preclinical/clinical development as novel therapeutic agents to treat cancers. There are important aspects of HGF/c-Met biology that need to be carefully addressed for successful development of these therapeutic antibodies targeting the HGF/c-Met signaling pathway. These include unwanted activation of c-Met by bivalent anti-c-Met antibodies and the recent failure of the Phase III study of onartuzumab in combination with erlotinib in NSCLC.

A monovalent antibody, onartuzumab (MetMAb™), was designed to address issues reported for several bivalent anti-c-Met reagents that induce unwanted stimulation of the c-Met signaling by mimicking c-Met dimerization.[@b69-itt-4-035],[@b77-itt-4-035] Onartuzumab, the one-armed humanized antibody against c-Met, blocks the interaction between the HGF-α chain and the Sema domain (homologous to semaphorins) of the c-Met receptor, demonstrated by crystallographic, structural, and biochemical analysis.[@b69-itt-4-035] However, despite concerns regarding c-Met activation by bivalent anti-c-Met antibodies and the development of the one-armed antibody, onartuzumab, clinical trials are still ongoing for two bivalent antibodies against c-Met (emibetuzumab and ARGX-111).[@b74-itt-4-035],[@b75-itt-4-035] More important aspects to consider for the development of HGF/c-Met inhibitors include patient stratification and identification of effective combinations of inhibitors targeting the HGF/c-Met pathway along with other interacting signaling pathways such as the EGFR pathway. Since alterations in HGF/c-Met signaling are closely related to tumorigenesis, tumor progression, and metastasis, it is critical to more accurately detect c-Met expression levels and alterations. In the Phase II study of onartuzumab in NSCLC, it has been demonstrated that the intensity of c-Met labeling detected via immunohistochemistry can successfully identify target patient groups for treatment.[@b70-itt-4-035] Immunohistochemistry-based detection of c-Met expression levels was also important for patient stratification in the Phase I and II trials of rilotumumab.[@b61-itt-4-035],[@b62-itt-4-035] However, the same strategy has failed to meet the initial goal in the Phase III study of onartuzumab in combination with erlotinib in NSCLC, possibly resulting from the recruitment of nonspecific patient groups rather than from ineffectiveness of the antibodies.[@b71-itt-4-035],[@b72-itt-4-035]

In addition to immunohistochemistry, different detection methods and other specific targets have also been examined. Elevated c-Met expression levels have been detected via Western blotting of serum proteins from patients with hepatocellular carcinoma and tissues from patients with colorectal cancer and metastasis to the liver.[@b78-itt-4-035],[@b79-itt-4-035] Phosphorylated c-Met (the active form of c-Met) has been intensively examined in preclinical and clinical studies and via in silico modeling. Antibodies that specifically recognize phosphorylated c-Met can be used to detect this pharmacodynamic biomarker.[@b80-itt-4-035]--[@b82-itt-4-035] In addition to the development of better detection methods and detecting antibodies, well defined scoring systems and minimization of interobserver differences are all required for effective patient diagnosis and stratification.

Although no significant correlation between a high *MET* gene copy number and patient response to onartuzumab has been reported from clinical trials, results from both preclinical and clinical studies with small-molecule inhibitors have demonstrated a correlation between a high copy number or specific mutation of *MET* gene and increased clinical response.[@b83-itt-4-035]--[@b85-itt-4-035] Due to the association between *MET* gene amplification/mutation and poor clinical outcomes, various technologies including next-generation sequencing are under development.[@b86-itt-4-035]

As reported from studies in NSCLC, inhibitors of the HGF/c-Met pathway may become more potent when combined with antagonists of other signaling pathways. Most clinical trials with anti-c-Met monoclonal antibodies were designed in combination with chemical inhibitors of other signaling pathways. Clinical trials of onartuzumab were conducted in combination with erlotinib, an EGFR inhibitor, to overcome EGFR-mediated resistance.[@b70-itt-4-035],[@b71-itt-4-035] Synergistic effects of dual inhibition of the HGF/c-Met and VEGF signaling pathways have been reported in preclinical studies, suggesting that combination of HGF/c-Met and VEGF/VEGFR inhibition may allow more effective treatment of human cancers.[@b87-itt-4-035]--[@b89-itt-4-035] The efficacy of onartuzumab and rilotumumab are being evaluated in combination with bevacizumab or panitumumab in the clinical settings of glioblastoma multiforme and metastatic colorectal cancer.[@b86-itt-4-035] Successful clinical development of candidates requires a better understanding of the interactions between signaling pathways. The use of two or more therapeutic agents in combination should be carefully designed because this combination treatment may elevate the risk of adverse effects and increase the treatment cost.

Results from clinical studies reflect the highly complex nature of HGF/c-Met signaling in human cancers and suggest that successful development of antibody-based therapeutics targeting the HGF/c-Met signaling pathway requires a better understanding of the pathways involved in the diseases, along with more careful analyses of the clinical data.

Conclusion
==========

Studies carried out over the past two decades have demonstrated that the HGF/c-Met signaling pathway is a promising therapeutic target for treating cancers. Therapeutic agents designed to target HGF/c-Met-mediated signaling cascades have been developed and evaluated in preclinical and clinical studies. In clinical trials in lung, gastric, prostate and renal cancers, inhibitors of the HGF/c-Met signaling pathway have yielded promising results. Like inhibitors of other RTK signaling pathways, inhibitors of the HGF/c-Met signaling pathway are divided into two groups, ie, small-molecule compounds suppressing the tyrosine kinase activity of c-Met and biologics such as monoclonal antibodies that specifically bind to HGF or c-Met.

Among the therapeutic agents targeting HGF or c-Met, a small-molecule inhibitor, cabozantinib (XL184, Exelixis, South San Francisco, CA, USA) became the first agent approved by the FDA for the clinical treatment of progressive metastatic medullary thyroid cancer (in November 2012). In addition, several small-molecule inhibitors of c-Met, including tivantinib (ARQ 197, ArQule, Woburn, MA, USA), golvatinib (E7050, Eisai, Tokyo, Japan), and foretinib (GSK 1363089, GlaxoSmithKline, Brentford, UK) are currently being evaluated in clinical studies for treatment of hepatocellular carcinoma.[@b90-itt-4-035]

In contrast with the success of cabozantinib, an antibody-based inhibitor of c-Met, onartuzumab failed to improve the clinical benefit in a recent Phase III study in NSCLC. However, the failure in this Phase III trial suggests several key issues to consider for successful clinical development of antibody-based HGF or c-Met inhibitors. Challenges to face for effective clinical application of HGF/c-Met-targeted therapeutics include advances in analytical methods to identify specific patient groups, more careful selection of target populations, development of biomarkers for HGF/c-Met signaling, and identification of effective combination therapies with other RTK inhibitors.
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![HGF/c-Met signaling cascades.\
**Notes:** Upon binding of HGF to its receptor c-Met, c-Met is dimerized and activated by phosphorylation of Tyr 1234 and Tyr 1235 residues. The other two tyrosines (Tyr 1349 and Tyr 1356) in the C-terminal tail are also phosphorylated, providing a docking site for multiple substrates of downstream signal cascades such as GAB1 and GRB2. The activated HGF/c-Met signaling pathway regulates diverse cellular processes including cell proliferation, differentiation, migration, invasion, and survival.\
**Abbreviations:** GRB2, growth factor receptor-bound protein 2; GAB1, GRB2-associated binding protein 1; HGF, hepatocyte growth factor; mTOR, mammalian target of rapamycin; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; STAT3, signal transducer and activator of transcription 3.](itt-4-035Fig1){#f1-itt-4-035}

###### 

Expression and mutation pattern of HGF/c-Met in human cancers

  Tumor types                                               Expression[a](#tfn1-itt-4-035){ref-type="table-fn"}   Mutation[b](#tfn2-itt-4-035){ref-type="table-fn"}   Association                                      
  --------------------------------------------------------- ----------------------------------------------------- --------------------------------------------------- ------------- ---- ----------- ----------------- ----
  Carcinoma                                                                                                                                                                                                            
   Breast cancer                                            25%--60%                                              \+                                                  \+            \+                                 \+
   Cervical cancer                                          30%--72%                                              \+                                                                                                   \+
   Cholangiocarcinoma                                       \+                                                    \+                                                                                                   
   Colorectal[e](#tfn5-itt-4-035){ref-type="table-fn"}      55%--78%[d](#tfn4-itt-4-035){ref-type="table-fn"}     \+                                                  \+            \+   4%--89%                       \+
   Endometrial                                              \+                                                    \+                                                                                                   
   Esophageal carcinoma                                     \+                                                    \+                                                                     \+                            \+
   Gastric carcinoma                                        75%--90%                                              \+                                                                \+   5%--10%     g                 \+
   Head and neck[f](#tfn6-itt-4-035){ref-type="table-fn"}   52%--68%                                              \+                                                                \+               s (11%--27%)      \+
   Renal cell/papillary renal                               54%--87%                                              \+                                                  \+                 Trisomy 7   g/s (13%--100%)   \+
   Hepatocellular                                           68%--69%                                              \+                                                  \+            \+               s (0%--30%)       \+
   Lung (non-small cell)                                    41%--72%                                              \+                                                                \+   5%--10%     8%--13%           \+
   Oral squamous cell carcinoma                                                                                   \+                                                  \+                                               \+
   Ovarian                                                  64%                                                   \+                                                  \+            \+               0%--4%            \+
   Pancreatic/gallbladder                                   \+                                                    \+                                                  \+                                               \+
   Prostate                                                 \+                                                    \+                                                  \+                                               \+
   Thyroid                                                  40%--91%                                              \+                                                  \+                             6%--10%           \+
  Sarcomas                                                  20%--87%                                                                                                                                 0%--3%            
  Other tumor types                                                                                                                                                                                                    
   Glioblastoma/astrocytoma                                 54%--88%                                              \+                                                                \+   9%--20%     0%--9%            \+
   Medulloblastoma                                                                                                \+                                                                     \+                            
   Melanoma                                                 17%--39%                                              \+                                                                                                   
   Mesothelioma                                             74%--100%                                             \+                                                                                                   \+
   Multiple myeloma                                         48%--80%                                                                                                                                                   

**Notes:**

Range (%) of c-Met expression is determined by histological analysis using tissues from cancer patients;

level of amplification/mutation is determined by sequence analysis;

germline and somatic mutations in tumors indicate with "g" or "s", respectively;

colon cancer only;

include liver metastasis;

include lymph node metastasis.

**Abbreviation:** HGF, hepatocyte growth factor.

###### 

Monoclonal antibody therapeutics targeting HGF or c-Met under development

  Drug candidate              Company                                       Target                    Status        Active indication        Reference
  --------------------------- --------------------------------------------- ------------------------- ------------- ------------------------ ------------------------------------
  Rilotumumab (AMG-102)       Amgen                                         HGF                       Phase III     SCLC, gastric cancer     [@b61-itt-4-035], [@b62-itt-4-035]
  Ficlatuzumab (AV-299)       AVEO                                          HGF                       Phase II      Solid tumor, NSCLC, MM   [@b63-itt-4-035]--[@b67-itt-4-035]
  TAK-701                     Galaxy Biotech                                HGF                       Phase I       Solid tumor              [@b68-itt-4-035]
  Onartuzumab (MetMAb™)       Genentech                                     c-Met                     Phase III     Solid tumor              [@b69-itt-4-035]--[@b72-itt-4-035]
  Emibetuzumab (LY-2875358)   Eli Lilly                                     c-Met                     Phase II      NSCLC, gastric cancer    [@b73-itt-4-035], [@b74-itt-4-035]
  ARGX-111                    arGEN-X                                       c-Met                     Phase I       Cancer                   [@b75-itt-4-035]
  EM1-mAb                     Genmab and Janssen Research and Development   EGFR/c-Met (bispecific)   Preclinical   --                       [@b76-itt-4-035]

**Abbreviations:** SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; MM, multiple myeloma; HGF, hepatocyte growth factor; EGFR, epidermal growth factor receptor.
